Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.52 |
| ▸ | GUSB | P08236 | 3/20 | 0.47 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.44 |
| ▸ | IL4I1 | Q96RQ9 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | PLAT | P00750 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24852000 | 0.81 | EGFR (0.55) | EGFRERBB2GUSBPIP4K2AIL4I1 | |
| SCHEMBL24851907 | 0.78 | GUSB (0.47) | EGFRERBB2GUSBIL4I1HPGD | |
| SCHEMBL24851921 | 0.78 | GUSB (0.54) | EGFRERBB2GUSBIL4I1IDH1 | |
| SCHEMBL24851919 | 0.77 | IL4I1 (0.42) | EGFRERBB2GUSBPIP4K2AIL4I1 | |
| SCHEMBL24851999 | 0.77 | GUSB (0.56) | EGFRERBB2GUSBIL4I1HPGD | |
| SCHEMBL24851962 | 0.76 | IL4I1 (0.51) | EGFRERBB2IL4I1HPGDTSHR | |
| SCHEMBL24852507 | 0.76 | IL4I1 (0.51) | EGFRIL4I1HPGDTSHRCYP1A2 | |
| SCHEMBL24852002 | 0.75 | IL4I1 (0.44) | EGFRERBB2GUSBIL4I1HPGD | |
| SCHEMBL24852005 | 0.75 | GUSB (0.47) | EGFRERBB2GUSBPIP4K2AIL4I1 | |
| SCHEMBL24852008 | 0.74 | GUSB (0.51) | EGFRERBB2GUSBIL4I1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-08-29 | — | — | US | disclosed |
| EP-4362978-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023278222-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023278222-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL1RN | EGFR 1388/4885ERBB2 3567/4885GUSB 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.